Literature DB >> 31934129

Overexpression of ERBB3 promotes proliferation, migration, and angiogenesis in nasopharyngeal carcinoma.

Bingyue Duan1, Ziyu Zhu1, Bo You1, Si Shi1, Ying Shan1, Pan Jiang1,2, Qicheng Zhang1, Lili Bao1, Yong Yin1, Yiwen You1.   

Abstract

The purpose of this study is to investigate the role of ERBB3 in nasopharyngeal carcinoma (NPC). We investigated the expression level of ERBB3 in NPC by immunohistochemistry and western blot. CCK-8, cell cycle analysis, transwell assay and wound healing assay were used to detect the effect of ERBB3 on the proliferation and migration of NPC cells. HUVECs were used to study the effects of ERBB3 on angiogenesis in NPC. Our results showed that the expression level of ERBB3 in NPC was much higher than that in normal controls. ERBB3 promoted the proliferation and migration of NPC cells, while suppression of ERBB3 reduced angiogenesis. These results indicated that overexpression of ERBB3 promotes tumorigenesis and angiogenesis in NPC, which may provide an effective target in gene therapy for NPC. IJCEP
Copyright © 2019.

Entities:  

Keywords:  ERBB3; Nasopharyngeal carcinoma; angiogenesis; migration; proliferation

Year:  2019        PMID: 31934129      PMCID: PMC6949710     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

1.  c-erbB-2 gene amplification in nasopharyngeal carcinoma.

Authors:  H Yazici; M Altun; C Alatli; O Dogan; N Dalay
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

Review 2.  The enigmatic epidemiology of nasopharyngeal carcinoma.

Authors:  Ellen T Chang; Hans-Olov Adami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

3.  Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival.

Authors:  S Kapitanović; S Radosević; N Slade; M Kapitanović; S Andelinović; Z Ferencić; M Tavassoli; S Spaventi; K Pavelić; R Spaventi
Journal:  J Cancer Res Clin Oncol       Date:  2000-04       Impact factor: 4.553

Review 4.  Vascular endothelial growth factor (VEGF) signaling in tumor progression.

Authors:  Robert Roskoski
Journal:  Crit Rev Oncol Hematol       Date:  2007-02-26       Impact factor: 6.312

5.  ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.

Authors:  Kristine S Klos; Shannon L Wyszomierski; Menghong Sun; Ming Tan; Xiaoyan Zhou; Ping Li; Wentao Yang; Guosheng Yin; Walter N Hittelman; Dihua Yu
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

Review 6.  ErbB receptors and signaling pathways in cancer.

Authors:  Nancy E Hynes; Gwen MacDonald
Journal:  Curr Opin Cell Biol       Date:  2009-02-07       Impact factor: 8.382

7.  New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression.

Authors:  D F Roychowdhury; A Tseng; K K Fu; V Weinburg; N Weidner
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

8.  Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma.

Authors:  K Werther; I J Christensen; H J Nielsen
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

Review 9.  Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma.

Authors:  Zhuo Chen; Xin-Hua Xu
Journal:  Saudi Med J       Date:  2015-06       Impact factor: 1.484

10.  Egr-1 activation by cancer-derived extracellular vesicles promotes endothelial cell migration via ERK1/2 and JNK signaling pathways.

Authors:  Yae Jin Yoon; Dae-Kyum Kim; Chang Min Yoon; Jaesung Park; Yoon-Keun Kim; Tae-Young Roh; Yong Song Gho
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

View more
  1 in total

1.  UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway.

Authors:  Jingjie Sun; Kejia Wu; Siyuan Chen; Shiming Jiang; Yong Chen; Changzhu Duan
Journal:  Int J Med Sci       Date:  2021-06-26       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.